ORAMED PHARMACEUTICALS INC

For the period ended Mar 31, 2025. Filed May 15, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2025 · Filed May 15, 2025

ORMP$3.86-0.8%Stored close · as of Nov 6, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Changes in Equity

INTERIM CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY

U.S. Dollars in thousands

Common Stock · Additional paid-in · Accumulated · Total stockholders’ · Non- controlling · Total
Shares · $ · capital · deficit · equity · interests · equity
In thousands
BALANCE AS OF DECEMBER 31, 2024	39,920	$480	$322,401	$(176,616)	$146,265	$(918)		$145,347
CHANGES DURING THE THREE MONTHS ENDED MARCH 31, 2025
STOCK-BASED COMPENSATION	931	11	2,178	-	2,189	-		2,189
NET LOSS	-	-	-	(7,642)	(7,642)	(*	)	(7,642)
BALANCE AS OF MARCH 31, 2025	40,851	$491	$324,579	$(184,258)	$140,812	$(918)		$139,894

Common Stock · Additional paid-in · Accumulated · Total stockholders’ · Non- controlling · Total
	Shares	$	capital	deficit	equity	interests	equity
In thousands
BALANCE AS OF DECEMBER 31, 2023	40,339	$485	$320,892	$(157,556)	$163,821	$(928)	$162,893
CHANGES DURING THE THREE MONTHS ENDED MARCH 31, 2024
STOCK-BASED COMPENSATION	180	2	1,280	-	1,282	-	1,282
STOCK-BASED COMPENSATION OF SUBSIDIARY	-	-	-	-	-	12	12
NET INCOME	-	-	-	1,536	1,536	(2)	1,534
BALANCE AS OF MARCH 31, 2024	40,519	$487	$322,172	$(156,020)	$166,639	$(918)	$165,721

(*)	represent amounts less than $1

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.